Form 8-K - Current report:
SEC Accession No. 0001104659-24-132482
Filing Date
2024-12-30
Accepted
2024-12-30 16:01:34
Documents
17
Period of Report
2024-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431815d2_8k.htm   iXBRL 8-K 31494
2 EXHIBIT 1.1 tm2431815d2_ex1-1.htm EX-1.1 212194
3 EXHIBIT 5.1 tm2431815d2_ex5-1.htm EX-5.1 7311
7 GRAPHIC tm2431815d2_ex5-1img001.jpg GRAPHIC 6960
8 GRAPHIC tm2431815d2_ex5-1img002.jpg GRAPHIC 5315
  Complete submission text file 0001104659-24-132482.txt   502023

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eyen-20241230.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20241230_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20241230_pre.xml EX-101.PRE 22359
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2431815d2_8k_htm.xml XML 3666
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 241589654
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)